Document,Word,TFIDFVal
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk prediction models,0.1339574398248474
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx xxx models,0.09504680782467546
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,and composite endpoints,0.09504680782467546
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk of bias,0.09504680782467546
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction models for,0.09504680782467546
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,all cause mortality,0.07688588499314933
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prospero id crdxxx,0.05613617582450349
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,in prospero id,0.05613617582450349
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registered in prospero,0.05613617582450349
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,was registered in,0.05613617582450349
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation of the,0.11954541762239483
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac pathological assessment,0.07060544942280779
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,reproducible cardiac pathological,0.07060544942280779
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,and reproducible cardiac,0.07060544942280779
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,efficient and reproducible,0.07060544942280779
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,accurate efficient and,0.07060544942280779
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,deliver accurate efficient,0.07060544942280779
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,to deliver accurate,0.07060544942280779
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,methods to deliver,0.07060544942280779
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,advanced machine learning,0.07060544942280779
Physiological Assessment of Coronary Lesions in 2020.,coronary physiological assessment,0.1207528300636465
Physiological Assessment of Coronary Lesions in 2020.,improve patient care,0.07131856666099871
Physiological Assessment of Coronary Lesions in 2020.,and improve patient,0.07131856666099871
Physiological Assessment of Coronary Lesions in 2020.,practice and improve,0.07131856666099871
Physiological Assessment of Coronary Lesions in 2020.,refine clinical practice,0.07131856666099871
Physiological Assessment of Coronary Lesions in 2020.,further refine clinical,0.07131856666099871
Physiological Assessment of Coronary Lesions in 2020.,will further refine,0.07131856666099871
Physiological Assessment of Coronary Lesions in 2020.,that will further,0.07131856666099871
Physiological Assessment of Coronary Lesions in 2020.,future that will,0.07131856666099871
Physiological Assessment of Coronary Lesions in 2020.,technological future that,0.07131856666099871
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,such as hypertension,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,conditions such as,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,of conditions such,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,management of conditions,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,in the management,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,ai in the,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,of ai in,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,trials of ai,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,and trials of,0.14585483317427897
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,in and trials,0.14585483317427897
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",of therapeutic interest,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",tissues of therapeutic,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",multiple tissues of,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",into multiple tissues,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mutations into multiple,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",point mutations into,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",targeted point mutations,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",of targeted point,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",introduction of targeted,0.08148971570540751
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",efficient introduction of,0.08148971570540751
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west nile virus,0.1467767590716777
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology are addressed,0.06993991213347461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv pathology are,0.06993991213347461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,into wnv pathology,0.06993991213347461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,research into wnv,0.06993991213347461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,for research into,0.06993991213347461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,directions for research,0.06993991213347461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,future directions for,0.06993991213347461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,and future directions,0.06993991213347461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,gaps and future,0.06993991213347461
Photoplethysmography based atrial fibrillation detection: a review.,applications the author,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,clinical applications the,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,towards clinical applications,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,challenges towards clinical,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,and challenges towards,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,limitations and challenges,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,their limitations and,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,of their limitations,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,discussion of their,0.07376672959029835
Photoplethysmography based atrial fibrillation detection: a review.,by discussion of,0.07376672959029835
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow map analysis,0.10781049152716972
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",to use the,0.10781049152716972
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",the flow map,0.10781049152716972
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",of single cell,0.10781049152716972
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis of single,0.10781049152716972
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dimensional single cell,0.10781049152716972
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",high dimensional single,0.10781049152716972
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx to complete,0.06367461303128734
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",min and xxx,0.06367461303128734
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx min and,0.06367461303128734
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,and field use,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,laboratory and field,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,diagnostic laboratory and,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,for diagnostic laboratory,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,applicable for diagnostic,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,directly applicable for,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,method directly applicable,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,this method directly,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,making this method,0.06919826239600992
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequencers making this,0.06919826239600992
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci auc xxx,0.11727788020332983
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx loci auc,0.11727788020332983
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx controls from,0.11727788020332983
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma and xxx,0.11727788020332983
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,with asthma and,0.11727788020332983
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,subjects with asthma,0.11727788020332983
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx subjects with,0.11727788020332983
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,auc xxx xxx,0.10736187653832147
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,and xxx controls,0.09486918935969378
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,optimal subset of,0.09461905530646499
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,of ecg signal,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,excerpts of ecg,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,short excerpts of,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,using short excerpts,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,system using short,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,alarming system using,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia alarming system,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,invasive hypoglycemia alarming,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,non invasive hypoglycemia,0.07678375686112181
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,time non invasive,0.07678375686112181
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,early stage nsclc,0.14209622150175646
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,with early stage,0.14209622150175646
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients with early,0.14209622150175646
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,received rv vxxxgy,0.10082151670970356
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,had received rv,0.10082151670970356
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,who had received,0.10082151670970356
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients who had,0.10082151670970356
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc undergoing sabr,0.10082151670970356
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage nsclc undergoing,0.10082151670970356
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os in patients,0.10082151670970356
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,in various tissues,0.10092839191301205
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl sulfate levels,0.10092839191301205
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,serum indoxyl sulfate,0.10092839191301205
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,in serum indoxyl,0.10092839191301205
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,pattern of galactosidase,0.10092839191301205
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,in galactosidase in,0.10092839191301205
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,increase in galactosidase,0.10092839191301205
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,of uremic toxicity,0.10092839191301205
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,in response to,0.08634005117586405
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,further investigation published,0.05960993413439328
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx xxx xxx,0.12488932955019659
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy copyright xxx,0.08548577288727174
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life expectancy copyright,0.08548577288727174
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,of life expectancy,0.08548577288727174
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,predictor of life,0.08548577288727174
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age is an,0.08548577288727174
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,for age is,0.08548577288727174
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,normal for age,0.08548577288727174
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,patterns normal for,0.08548577288727174
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,from patterns normal,0.08548577288727174
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf early screening,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,for hf early,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,analysis for hf,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs analysis for,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,of hs analysis,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,effectiveness of hs,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,demonstrates the effectiveness,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance demonstrates the,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,good performance demonstrates,0.07103522030548032
Gated recurrent unit-based heart sound analysis for heart failure screening.,the good performance,0.07103522030548032
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,the som based,0.12473140354039129
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som based subgroups,0.12473140354039129
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd risk assessment,0.12473140354039129
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,elsevier all rights,0.07366837624779968
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,by elsevier all,0.07366837624779968
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,assessment copyright xxx,0.07366837624779968
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk assessment copyright,0.07366837624779968
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,advance chd risk,0.07366837624779968
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,not advance chd,0.07366837624779968
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,may not advance,0.07366837624779968
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angptlxxx and angptlxxx,0.14242353610359612
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg rich lipoproteins,0.1252535261082806
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,reduction of plasma,0.10105375620382902
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,marked reduction of,0.10105375620382902
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,mutations of angptlxxx,0.10105375620382902
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,function mutations of,0.10105375620382902
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,of function mutations,0.10105375620382902
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich lipoproteins and,0.10105375620382902
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,loss of function,0.09250952420421636
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,for the treatment,0.08644729512456475
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,of breast cancer,0.16358158329116776
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,ikkε and its,0.1319765914059099
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,associated with obesity,0.1319765914059099
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer associated with,0.1319765914059099
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast cancer associated,0.1319765914059099
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,risk of breast,0.1319765914059099
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast cancer and,0.12081779179418944
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,xxx xxx license,0.07794750091499046
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cc by xxx,0.07794750091499046
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,the cc by,0.07794750091499046
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older adults in,0.15900051009777677
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults in general,0.1398320466378237
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,use and perceived,0.11281561477323473
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,of use and,0.11281561477323473
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ease of use,0.11281561477323473
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived ease of,0.11281561477323473
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology acceptance behavior,0.06663071944869267
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users technology acceptance,0.06663071944869267
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older users technology,0.06663071944869267
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,determining older users,0.06663071944869267
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx value xxx,0.13413410845502227
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx xxx value,0.13413410845502227
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,value xxx xxx,0.1147461637793363
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx vs xxx,0.10850463968611117
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx xxx vs,0.10850463968611117
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,higher prevalence of,0.10787590959413554
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs xxx xxx,0.10340494317800364
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence of undiagnosed,0.0870336046185879
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,with higher prevalence,0.0870336046185879
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary behaviours and,0.0870336046185879
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",months xxx xxx,0.1437539722162883
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx months xxx,0.1437539722162883
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",at xxx months,0.1437539722162883
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx at xxx,0.13159937910047795
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",post menopausal women,0.10199774039531107
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density lipoprotein cholesterol,0.08250867879814316
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx john wiley,0.0602415085743338
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",investigation xxx john,0.0602415085743338
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",further investigation xxx,0.0602415085743338
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",needs further investigation,0.0602415085743338
Heart Failure With Mid-range Ejection Fraction.,heart failure with,0.1484049389769284
Heart Failure With Mid-range Ejection Fraction.,hfref and hfpef,0.12308924374918846
Heart Failure With Mid-range Ejection Fraction.,ejection fraction hfmref,0.12308924374918846
Heart Failure With Mid-range Ejection Fraction.,range ejection fraction,0.12308924374918846
Heart Failure With Mid-range Ejection Fraction.,mid range ejection,0.12308924374918846
Heart Failure With Mid-range Ejection Fraction.,management and prognosis,0.12308924374918846
Heart Failure With Mid-range Ejection Fraction.,pathophysiology management and,0.12308924374918846
Heart Failure With Mid-range Ejection Fraction.,and prognosis of,0.11268188142285776
Heart Failure With Mid-range Ejection Fraction.,of patients with,0.10529774033914036
Heart Failure With Mid-range Ejection Fraction.,of this condition,0.07269849022131748
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,of coronary prediction,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models of coronary,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,classification models of,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,algorithm classification models,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,efficient algorithm classification,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,obtain efficient algorithm,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,to obtain efficient,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling to obtain,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,and enabling to,0.06888008991923975
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,medicine and enabling,0.06888008991923975
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory cell subsets,0.1766447236998254
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,between memory cell,0.1425158508353944
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,the clonal overlap,0.1425158508353944
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,in immune responses,0.08417215731255126
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,roles in immune,0.08417215731255126
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,separate roles in,0.08417215731255126
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,have separate roles,0.08417215731255126
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,likely have separate,0.08417215731255126
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,and likely have,0.08417215731255126
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,antigens and likely,0.08417215731255126
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,of mesenchyme free,0.13850870839583027
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation of mesenchyme,0.13850870839583027
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,therapeutic screening applications,0.0818054744360875
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,and therapeutic screening,0.0818054744360875
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,modeling and therapeutic,0.0818054744360875
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease modeling and,0.0818054744360875
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,for disease modeling,0.0818054744360875
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,potential for disease,0.0818054744360875
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,future potential for,0.0818054744360875
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,their future potential,0.0818054744360875
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,comparable to bnp,0.11995383920946592
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lpc xxx xxx,0.11995383920946592
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolomics and machine,0.11995383920946592
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,and machine learning,0.10981157958496841
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,of proposed markers,0.07084666979145643
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,utility of proposed,0.07084666979145643
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinical utility of,0.07084666979145643
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,confirm clinical utility,0.07084666979145643
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,to confirm clinical,0.07084666979145643
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,crucial to confirm,0.07084666979145643
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce us imaging,0.14430917797565063
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,of the uca,0.11642773614628224
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative dce us,0.11642773614628224
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,biology published by,0.06876409651981825
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,medicine biology published,0.06876409651981825
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,in medicine biology,0.06876409651981825
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound in medicine,0.06876409651981825
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,for ultrasound in,0.06876409651981825
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,federation for ultrasound,0.06876409651981825
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,world federation for,0.06876409651981825
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac contractile function,0.14978552919455018
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,of cardiac contractile,0.10627731036728137
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,was an independent,0.10627731036728137
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,all xxx xxx,0.10627731036728137
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast at xxx,0.10627731036728137
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,of chast at,0.10627731036728137
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,in ami patients,0.10627731036728137
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,early stage ami,0.10627731036728137
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function and remodeling,0.10627731036728137
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,of cardiac function,0.10627731036728137
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stratification of individuals,0.10861971376606443
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,the potential of,0.09943576980383485
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health risk assessment,0.06415255272146068
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,preventative health risk,0.06415255272146068
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,personalized preventative health,0.06415255272146068
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,towards personalized preventative,0.06415255272146068
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,step towards personalized,0.06415255272146068
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,essential step towards,0.06415255272146068
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,an essential step,0.06415255272146068
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stages an essential,0.06415255272146068
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,in food allergy,0.13177155689312425
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk of severe,0.10631246240018175
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,following allergen exposure,0.10631246240018175
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,future copyright xxx,0.06278985289691286
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,the future copyright,0.06278985289691286
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,in the future,0.06278985289691286
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,research in the,0.06278985289691286
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,of research in,0.06278985289691286
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,area of research,0.06278985289691286
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,important area of,0.06278985289691286
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,semmelweis crt score,0.12562137971907258
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing crt implantation,0.12562137971907258
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients undergoing crt,0.12562137971907258
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx xxx xxx,0.1206230730505904
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ci xxx xxx,0.1204149441767422
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx ci xxx,0.1204149441767422
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx xxx ci,0.1204149441767422
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,the semmelweis crt,0.1013505381808213
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,deaths in the,0.1013505381808213
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx deaths in,0.1013505381808213
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,specificity of xxx,0.1127384124026452
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,sensitivity of xxx,0.1127384124026452
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,the proposed method,0.1127384124026452
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,of xxx xxx,0.11198345990118154
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx xxx for,0.09119709339727755
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ventricular tachycardia arrhythmia,0.06658512248495796
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,of ventricular tachycardia,0.06658512248495796
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,type of ventricular,0.06658512248495796
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm type of,0.06658512248495796
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,for alarm type,0.06658512248495796
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,in north china,0.11895734811302575
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood glucose control,0.11895734811302575
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx xxx respectively,0.0962277555178835
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,sensitivity and accuracy,0.09597403944121778
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en and machine,0.09597403944121778
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,the en and,0.09597403944121778
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine learning models,0.087859304376133
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine learning algorithms,0.087859304376133
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,and machine learning,0.087859304376133
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx xxx xxx,0.08281148145479986
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,ci xxx xxx,0.10857591760814367
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx ci xxx,0.10857591760814367
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx xxx ci,0.10857591760814367
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx and home,0.09598241712766192
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost xxx xxx,0.09598241712766192
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hospitalization xxx xxx,0.09598241712766192
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx hf hospitalization,0.09598241712766192
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx xxx hf,0.09598241712766192
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mortality xxx xxx,0.09598241712766192
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,from network xxx,0.09598241712766192
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,in fhs and,0.15286347053557947
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,and nacc respectively,0.12332928552142698
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,fhs and nacc,0.12332928552142698
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx accuracy in,0.12332928552142698
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,development of ad,0.12332928552142698
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,and delayed recall,0.12332928552142698
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,immediate and delayed,0.12332928552142698
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx xxx xxx,0.1215593701734854
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx xxx accuracy,0.11290162733803315
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,unsupervised machine learning,0.11290162733803315
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,between the two,0.10189141585073053
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,of hnd patients,0.10189141585073053
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,rafiq et al,0.06017871158550654
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,xxx rafiq et,0.06017871158550654
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization xxx rafiq,0.06017871158550654
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care utilization xxx,0.06017871158550654
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,on care utilization,0.06017871158550654
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,interventions on care,0.06017871158550654
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care interventions on,0.06017871158550654
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated care interventions,0.06017871158550654
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,age and sex,0.13183693847981168
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc age and,0.13183693847981168
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc cut offs,0.1063652118526452
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,the first xxx,0.1063652118526452
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,linear combination of,0.1063652118526452
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,patients and xxx,0.1063652118526452
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,consisting of xxx,0.1063652118526452
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cohort consisting of,0.1063652118526452
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,improve lqts diagnosis,0.1063652118526452
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,of the first,0.09737188908170485
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers xxx xxx,0.12612965495714856
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc hf guidelines,0.10176061144253987
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,low proportion of,0.10176061144253987
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx xxx angiotensin,0.10176061144253987
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,antagonists xxx xxx,0.10176061144253987
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,receptor antagonists xxx,0.10176061144253987
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,beta blockers xxx,0.10176061144253987
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,level of complexity,0.10176061144253987
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,the linx registry,0.10176061144253987
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,proportion of patients,0.09315661387481211
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,of subjects with,0.11717974801133152
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,prevalence of subjects,0.11717974801133152
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,in xxx xxx,0.11717974801133152
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,the prevalence of,0.11398384717572488
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx xxx mg,0.10727204155611092
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,subjects with albuminuria,0.09453988287185126
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx xxx microalbuminuria,0.09453988287185126
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blood pressure was,0.09453988287185126
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mmol creatinine xxx,0.09453988287185126
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albumin mmol creatinine,0.09453988287185126
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,of hcc patients,0.13667319986394524
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,was able to,0.11026707708578626
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features was able,0.11026707708578626
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx features was,0.11026707708578626
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,were extracted from,0.11026707708578626
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features were extracted,0.11026707708578626
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,from adjacent normal,0.11026707708578626
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc from adjacent,0.11026707708578626
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,auc xxx xxx,0.10094384632294569
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prediction after hepatectomy,0.06512551203571064
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,for heart failure,0.11990223995401639
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,from xxx xxx,0.11204494253499589
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,the use of,0.1058775829215918
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,function in xxx,0.10567099830384061
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive function in,0.10567099830384061
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,of cognitive function,0.10567099830384061
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,levels of cognitive,0.10567099830384061
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people in xxx,0.10567099830384061
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx people in,0.10567099830384061
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,in nursing homes,0.10567099830384061
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type xxx diabetes,0.15092065567553622
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx diabetes and,0.1409161321424177
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes and cvd,0.12392784871974945
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,for type xxx,0.09998420803390569
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,information on the,0.09998420803390569
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,time xxx xxx,0.09998420803390569
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,up time xxx,0.09998420803390569
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,follow up time,0.09998420803390569
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,median follow up,0.09998420803390569
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx median follow,0.09998420803390569
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,of multiple igfxxx,0.1364740939898239
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mouse skeletal muscle,0.11010643972021769
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,and mouse skeletal,0.11010643972021769
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,human and mouse,0.11010643972021769
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,in human and,0.11010643972021769
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants can be,0.11010643972021769
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna variants can,0.11010643972021769
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,or igfxxx mrna,0.11010643972021769
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,igfxxx or igfxxx,0.11010643972021769
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple igfxxx or,0.11010643972021769
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,at xxx xxx,0.11840431325107795
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group xxx xxx,0.11327004048532774
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,in group xxx,0.11327004048532774
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,均p xxx xxx,0.10734295755970844
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,those in group,0.10734295755970844
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,than those in,0.10734295755970844
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group at xxx,0.10734295755970844
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx were significantly,0.10734295755970844
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,higher than those,0.09175285233347562
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,in group at,0.09175285233347562
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,compared to hfd,0.14695302282711484
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx xxx fold,0.14695302282711484
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hfd xxx xxx,0.14058081490470575
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,to hfd xxx,0.14058081490470575
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decrease compared to,0.13322464072024204
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,for both mimetics,0.11387557288409329
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx for both,0.11387557288409329
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx fold auc,0.11387557288409329
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf xxx xxx,0.11387557288409329
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold decrease compared,0.1001471907772205
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,of potassium channels,0.15917550310914932
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides of potassium,0.13998594319395732
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand peptides of,0.13998594319395732
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,the prediction of,0.09661529316242182
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,primary structure information,0.06670405198227433
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,only primary structure,0.06670405198227433
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,using only primary,0.06670405198227433
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,reliability using only,0.06670405198227433
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high reliability using,0.06670405198227433
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,with high reliability,0.06670405198227433
Machine learning: a long way from implementation in cardiovascular disease.,interests none declared,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,competing interests none,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,statement competing interests,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,interest statement competing,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,of interest statement,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,conflict of interest,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,xxx conflict of,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,pmid xxx conflict,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,heartjnl xxx xxx,0.2752886229274925
Machine learning: a long way from implementation in cardiovascular disease.,xxx heartjnl xxx,0.2752886229274925
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx xxx xxx,0.12197694342516881
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,composite end point,0.10382923511535769
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,the composite end,0.10382923511535769
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,using machine learning,0.09505033261342051
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,published by bmj,0.061323218859815856
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,permissions published by,0.061323218859815856
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,and permissions published,0.061323218859815856
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rights and permissions,0.061323218859815856
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,see rights and,0.061323218859815856
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,use see rights,0.061323218859815856
Machine Learning in Fetal Cardiology: What to Expect.,of fetal cardiac,0.12096498041439258
Machine Learning in Fetal Cardiology: What to Expect.,the fetal heart,0.12096498041439258
Machine Learning in Fetal Cardiology: What to Expect.,of the fetal,0.12096498041439258
Machine Learning in Fetal Cardiology: What to Expect.,assessment of the,0.11073722743107488
Machine Learning in Fetal Cardiology: What to Expect.,to improve the,0.11073722743107488
Machine Learning in Fetal Cardiology: What to Expect.,in the diagnosis,0.11073722743107488
Machine Learning in Fetal Cardiology: What to Expect.,karger ag basel,0.07144386607571108
Machine Learning in Fetal Cardiology: What to Expect.,xxx karger ag,0.07144386607571108
Machine Learning in Fetal Cardiology: What to Expect.,abnormalities xxx karger,0.07144386607571108
Machine Learning in Fetal Cardiology: What to Expect.,and abnormalities xxx,0.07144386607571108
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,living foam cells,0.16236385962484506
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,related metabolic diseases,0.07736724906337497
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,ld related metabolic,0.07736724906337497
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,against ld related,0.07736724906337497
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,drugs against ld,0.07736724906337497
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,new drugs against,0.07736724906337497
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,explore new drugs,0.07736724906337497
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,to explore new,0.07736724906337497
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,tool to explore,0.07736724906337497
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,promising tool to,0.07736724906337497
Supervised machine learning models applied to disease diagnosis and prognosis.,and heart disease,0.24045231799944417
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer and heart,0.24045231799944417
Supervised machine learning models applied to disease diagnosis and prognosis.,the important variables,0.17060810724490832
Supervised machine learning models applied to disease diagnosis and prognosis.,heart disease data,0.17060810724490832
Supervised machine learning models applied to disease diagnosis and prognosis.,breast cancer and,0.1561829606291306
Supervised machine learning models applied to disease diagnosis and prognosis.,licensee aims press,0.10076389649037246
Supervised machine learning models applied to disease diagnosis and prognosis.,author licensee aims,0.10076389649037246
Supervised machine learning models applied to disease diagnosis and prognosis.,the author licensee,0.10076389649037246
Supervised machine learning models applied to disease diagnosis and prognosis.,xxx the author,0.10076389649037246
Supervised machine learning models applied to disease diagnosis and prognosis.,respectively xxx the,0.10076389649037246
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,knockdown of gαs,0.10592607402669066
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,non genomic actions,0.10592607402669066
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,of federation of,0.0625616456991409
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,behalf of federation,0.0625616456991409
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inc on behalf,0.0625616456991409
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,periodicals inc on,0.0625616456991409
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,by wiley periodicals,0.0625616456991409
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,published by wiley,0.0625616456991409
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,journal published by,0.0625616456991409
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,faseb journal published,0.0625616456991409
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",and improved survival,0.11787229636097882
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",injury xxx federation,0.06961727705325471
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ injury xxx,0.06961727705325471
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased organ injury,0.06961727705325471
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",and decreased organ,0.06961727705325471
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clearance and decreased,0.06961727705325471
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen clearance and,0.06961727705325471
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",enhanced pathogen clearance,0.06961727705325471
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",activity enhanced pathogen,0.06961727705325471
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",phagocytic activity enhanced,0.06961727705325471
Innovations in pharmacological treatment of heart failure.,be added to,0.13986339819717417
Innovations in pharmacological treatment of heart failure.,should be added,0.13986339819717417
Innovations in pharmacological treatment of heart failure.,drugs pmid xxx,0.08260557605566193
Innovations in pharmacological treatment of heart failure.,perspective drugs pmid,0.08260557605566193
Innovations in pharmacological treatment of heart failure.,others perspective drugs,0.08260557605566193
Innovations in pharmacological treatment of heart failure.,and others perspective,0.08260557605566193
Innovations in pharmacological treatment of heart failure.,mecarbil and others,0.08260557605566193
Innovations in pharmacological treatment of heart failure.,omecamtiv mecarbil and,0.08260557605566193
Innovations in pharmacological treatment of heart failure.,with omecamtiv mecarbil,0.08260557605566193
Innovations in pharmacological treatment of heart failure.,done with omecamtiv,0.08260557605566193
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,the readmission risk,0.10760889464049322
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predict the readmission,0.10760889464049322
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,of copd patients,0.10760889464049322
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,day readmission risk,0.10760889464049322
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx day readmission,0.10760889464049322
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,the xxx day,0.10760889464049322
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,from the hospital,0.10760889464049322
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,to predict the,0.09851041680483796
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predicting the xxx,0.06355554666246178
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,in predicting the,0.06355554666246178
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,the tc induced,0.10821171420620371
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo mφ of,0.10821171420620371
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced fak dependent,0.08730452966520673
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tc induced fak,0.08730452966520673
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mφ proliferation and,0.08730452966520673
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,in mφ proliferation,0.08730452966520673
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,involved in mφ,0.08730452966520673
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,in the expression,0.08730452966520673
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory mo mφ,0.08730452966520673
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cdxxx cdxxx cdxxx,0.08730452966520673
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood disorders were,0.13093986196615673
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds and multimorbidity,0.13093986196615673
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr xxx xxx,0.10564145616988144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk following multimorbidity,0.10564145616988144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality risk following,0.10564145616988144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,year of care,0.10564145616988144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first year of,0.10564145616988144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,the first year,0.10564145616988144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident ncds and,0.10564145616988144
Mood disorders and increased risk of non-communicable disease in adults with HIV.,increased risk of,0.09037188207518086
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",or xxx xxx,0.14652689959022944
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",the most relevant,0.13413785170805453
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",for atrial fibrillation,0.11821697998101366
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",the study outcomes,0.11821697998101366
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",predictors for the,0.11821697998101366
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",relevant predictors for,0.11821697998101366
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",most relevant predictors,0.11821697998101366
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",identify the most,0.11821697998101366
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",to identify the,0.11821697998101366
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",loratadine and betahistine,0.11821697998101366
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,and automatically obtained,0.10571364265839846
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually and automatically,0.10571364265839846
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,between manually and,0.10571364265839846
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent deployment calcification,0.10571364265839846
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx xxx xxx,0.08505224187896034
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,including its doi,0.062436180310938824
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,publication including its,0.062436180310938824
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,original publication including,0.062436180310938824
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,the original publication,0.062436180310938824
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,of the original,0.062436180310938824
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx xxx kpa,0.12536160425067572
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress xxx xxx,0.12536160425067572
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber stress xxx,0.10114095296859807
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx xxx mmhg,0.10114095296859807
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure xxx xxx,0.10114095296859807
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx xxx ml,0.10114095296859807
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume xxx xxx,0.10114095296859807
Prediction of Left Ventricular Mechanics Using Machine Learning.,well as lv,0.10114095296859807
Prediction of Left Ventricular Mechanics Using Machine Learning.,of lv pressures,0.10114095296859807
Prediction of Left Ventricular Mechanics Using Machine Learning.,behavior of the,0.10114095296859807
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",and block neurodegeneration,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",regeneration and block,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neuronal regeneration and,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",to neuronal regeneration,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",contribute to neuronal,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",synergistically contribute to,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",could synergistically contribute,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",which could synergistically,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",xxx which could,0.07857281439636973
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hybrid xxx which,0.07857281439636973
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,response to tgf,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,for the patients,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,accounting for the,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,further accounting for,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,and il xxxf,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,xxxa and il,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,il xxxa and,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,the patients fibroblasts,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mapk signaling pathway,0.09843392199067859
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,of connective tissues,0.09843392199067859
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,axxxr and girk,0.12993076395383032
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate slowing in,0.10482732224733425
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced rate slowing,0.10482732224733425
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado induced rate,0.10482732224733425
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,prevented ado induced,0.10482732224733425
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,and girk mrna,0.10482732224733425
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,negative chronotropic effects,0.10482732224733425
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf copyright xxx,0.06191270519829617
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,in hf copyright,0.06191270519829617
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,bradycardia in hf,0.06191270519829617
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could organize the,0.10100662086478827
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiration could organize,0.10100662086478827
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced inspiration could,0.10100662086478827
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,that slow paced,0.10100662086478827
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,widespread brain areas,0.10100662086478827
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,relative to normal,0.10100662086478827
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,the cortical phase,0.10100662086478827
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,modulate cortical activity,0.059656137413514214
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,systematically modulate cortical,0.059656137413514214
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could systematically modulate,0.059656137413514214
Implications for REDUCE IT in clinical practice.,high risk patients,0.13731177478512704
Implications for REDUCE IT in clinical practice.,risk copyright xxx,0.08858885377523848
Implications for REDUCE IT in clinical practice.,ascvd risk copyright,0.08858885377523848
Implications for REDUCE IT in clinical practice.,high ascvd risk,0.08858885377523848
Implications for REDUCE IT in clinical practice.,at high ascvd,0.08858885377523848
Implications for REDUCE IT in clinical practice.,patients at high,0.08858885377523848
Implications for REDUCE IT in clinical practice.,therapy in patients,0.08858885377523848
Implications for REDUCE IT in clinical practice.,lowering therapy in,0.08858885377523848
Implications for REDUCE IT in clinical practice.,combination lipid lowering,0.08858885377523848
Implications for REDUCE IT in clinical practice.,guide combination lipid,0.08858885377523848
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,any repeat revascularization,0.1478329457107237
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,the xxx groups,0.11927068976749333
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,between the xxx,0.11927068976749333
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,repeat revascularization and,0.11927068976749333
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cumulative incidences of,0.11927068976749333
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,the cumulative incidences,0.11927068976749333
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,the occurrences of,0.11927068976749333
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,similar between the,0.10918619135387893
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,were similar between,0.10918619135387893
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,all cause death,0.10918619135387893
Women had favourable reverse left ventricle remodelling after TAVR.,regression of lvmi,0.10170448779887437
Women had favourable reverse left ventricle remodelling after TAVR.,months post tavr,0.10170448779887437
Women had favourable reverse left ventricle remodelling after TAVR.,xxx months post,0.10170448779887437
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling after tavr,0.10170448779887437
Women had favourable reverse left ventricle remodelling after TAVR.,lv remodelling after,0.10170448779887437
Women had favourable reverse left ventricle remodelling after TAVR.,xxx xxx xxx,0.06340841472795898
Women had favourable reverse left ventricle remodelling after TAVR.,investigation journal foundation,0.06006830886682833
Women had favourable reverse left ventricle remodelling after TAVR.,clinical investigation journal,0.06006830886682833
Women had favourable reverse left ventricle remodelling after TAVR.,for clinical investigation,0.06006830886682833
Women had favourable reverse left ventricle remodelling after TAVR.,society for clinical,0.06006830886682833
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,this risk is,0.106792867988204
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic cardiovascular disease,0.09135686710698586
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,patients copyright xxx,0.06307358817612431
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh patients copyright,0.06307358817612431
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,in fh patients,0.06307358817612431
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl in fh,0.06307358817612431
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,treat ldl in,0.06307358817612431
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,better treat ldl,0.06307358817612431
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,to better treat,0.06307358817612431
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,order to better,0.06307358817612431
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",of this syndrome,0.12482311402105743
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",and family concerns,0.07372254193505896
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient and family,0.07372254193505896
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",for patient and,0.07372254193505896
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",source for patient,0.07372254193505896
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",and source for,0.07372254193505896
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",morbidity and source,0.07372254193505896
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",for morbidity and,0.07372254193505896
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cause for morbidity,0.07372254193505896
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",as cause for,0.07372254193505896
Prime time for ticagrelor monotherapy.,nov xxx xxx,0.3817509821993612
Prime time for ticagrelor monotherapy.,xxx nov xxx,0.3817509821993612
Prime time for ticagrelor monotherapy.,med xxx nov,0.3817509821993612
Prime time for ticagrelor monotherapy.,engl med xxx,0.3817509821993612
Prime time for ticagrelor monotherapy.,on engl med,0.3817509821993612
Prime time for ticagrelor monotherapy.,comment on engl,0.3817509821993612
Prime time for ticagrelor monotherapy.,xxx xxx xxx,0.35439684752962813
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,the mir xxxa,0.1403313574806411
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,in atdcxxx cells,0.1403313574806411
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il xxx induced,0.1403313574806411
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir xxxa mimic,0.1132184556173031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,and the mir,0.1132184556173031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inhibited il xxx,0.1132184556173031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil inhibited il,0.1132184556173031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,used to detect,0.1132184556173031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury in atdcxxx,0.1132184556173031
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory injury in,0.1132184556173031
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx xxx μm,0.1451865131429258
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",icxxx xxx xxx,0.12768340972302625
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies copyright xxx,0.06646121460572627
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pharmacokinetic studies copyright,0.06646121460572627
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",by pharmacokinetic studies,0.06646121460572627
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ascertained by pharmacokinetic,0.06646121460572627
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",characteristics ascertained by,0.06646121460572627
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",absorption characteristics ascertained,0.06646121460572627
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oral absorption characteristics,0.06646121460572627
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",good oral absorption,0.06646121460572627
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",rxxx subtype and,0.1249998748569405
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",the lead compound,0.1249998748569405
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",the most active,0.1249998748569405
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",against hiv xxxvbxxx,0.1249998748569405
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",for anti hiv,0.1249998748569405
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx μm and,0.11443096608183274
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx xxx μm,0.11443096608183274
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",development copyright xxx,0.07382693973219825
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug development copyright,0.07382693973219825
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv drug development,0.07382693973219825
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",is able to,0.13387472356125582
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",the infection of,0.10800928402541611
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",for the treatment,0.0923974605506479
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",the treatment of,0.08326512925003027
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",of chagas disease,0.06379202308312976
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treatment of chagas,0.06379202308312976
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug for the,0.06379202308312976
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",candidate drug for,0.06379202308312976
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",be candidate drug,0.06379202308312976
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",to be candidate,0.06379202308312976
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect of dap,0.1462325731176408
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,of dap on,0.1286033609048203
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx mmp xxx,0.1037563818254022
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il xxxβ in,0.1037563818254022
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vitro and in,0.1037563818254022
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,in vitro and,0.1037563818254022
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effects of dap,0.1037563818254022
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,and in vivo,0.09498363916783596
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,of il xxx,0.08875927919617213
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,the effect of,0.08875927919617213
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx vs xxx,0.13463077706923995
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx xxx vs,0.13463077706923995
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,at xxx year,0.13427580679717413
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,one xxx xxx,0.13427580679717413
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without one xxx,0.13427580679717413
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,with without one,0.13427580679717413
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,compared with without,0.13427580679717413
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,with or without,0.13427580679717413
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,groups with or,0.13427580679717413
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx groups with,0.13427580679717413
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,rec xxx xxx,0.3630597820803008
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx rec xxx,0.3630597820803008
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx xxx rec,0.3630597820803008
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,indexed for medline,0.3105825781087265
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx indexed for,0.3105825781087265
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,pmid xxx indexed,0.3105825781087265
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx pmid xxx,0.3105825781087265
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx xxx pmid,0.3105825781087265
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,doi xxx xxx,0.3105825781087265
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx xxx xxx,0.1606037264805341
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx μg ml,0.16060561373199836
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx xxx μg,0.16060561373199836
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ecxxx xxx xxx,0.1295755979038001
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat aortic rings,0.1295755979038001
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus fruit extract,0.1295755979038001
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase activity and,0.1295755979038001
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx xxx xxx,0.11180468473849403
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",and xxx xxx,0.07699650511797311
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ltd all rights,0.07652943547468082
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",elsevier ltd all,0.07652943547468082
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female reproductive tract,0.1278070618962959
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",on hiv xxx,0.1278070618962959
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",of hiv xxx,0.11700080165369613
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv xxx fusion,0.10311393279923098
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv xxx entry,0.10311393279923098
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells from the,0.10311393279923098
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",upper female reproductive,0.10311393279923098
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",the upper female,0.10311393279923098
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptives on hiv,0.10311393279923098
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",of contraceptives on,0.10311393279923098
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma renin activity,0.2069334735477689
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated plasma renin,0.19610526290575936
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",the normalization of,0.11893398290278348
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac systolic function,0.11893398290278348
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically elevated plasma,0.11893398290278348
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",of elevated plasma,0.11893398290278348
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx xxx and,0.07233670298602737
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",selected hf patients,0.07024432622771191
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",appropriately selected hf,0.07024432622771191
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",in appropriately selected,0.07024432622771191
Sensor Networks for Aerospace Human-Machine Systems.,sensor networks for,0.09979243876105333
Sensor Networks for Aerospace Human-Machine Systems.,of sensor networks,0.09979243876105333
Sensor Networks for Aerospace Human-Machine Systems.,operator cognitive states,0.09979243876105333
Sensor Networks for Aerospace Human-Machine Systems.,the operator cognitive,0.09979243876105333
Sensor Networks for Aerospace Human-Machine Systems.,human machine systems,0.09979243876105333
Sensor Networks for Aerospace Human-Machine Systems.,cyber physical systems,0.09979243876105333
Sensor Networks for Aerospace Human-Machine Systems.,aerospace cyber physical,0.09979243876105333
Sensor Networks for Aerospace Human-Machine Systems.,space operations management,0.05893902190360715
Sensor Networks for Aerospace Human-Machine Systems.,and space operations,0.05893902190360715
Sensor Networks for Aerospace Human-Machine Systems.,uas and space,0.05893902190360715
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving detection system,0.10758079673134684
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,test retest reliability,0.10758079673134684
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving for gaming,0.10758079673134684
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,the third experiment,0.08679550941907167
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,in the third,0.08679550941907167
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high test retest,0.08679550941907167
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,the same day,0.08679550941907167
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,data of the,0.08679550941907167
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,of the craving,0.08679550941907167
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,the machine learning,0.07424995665775286
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,with muscular dystrophy,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,associated with muscular,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy associated with,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,for cardiomyopathy associated,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,applications for cardiomyopathy,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,their therapeutic applications,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,and their therapeutic,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inhibitors and their,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,trpvxxx inhibitors and,0.08780865432088455
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,of trpvxxx inhibitors,0.08780865432088455
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,after allograft reperfusion,0.13004282069893947
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,interstitial lung disease,0.10491772892372166
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,with pgd development,0.10491772892372166
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,associated with pgd,0.10491772892372166
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,obstructive pulmonary disease,0.08975276344774193
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic obstructive pulmonary,0.08975276344774193
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,is associated with,0.08088182731956284
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung transplant recipients,0.06196610083774525
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,in lung transplant,0.06196610083774525
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,injury in lung,0.06196610083774525
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,wnt catenin pathway,0.19031302831117708
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,the wnt catenin,0.17788424711339715
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,catenin pathway and,0.14306148660361265
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian clock disruption,0.11542110660342572
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pathway and pparγ,0.11542110660342572
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,of the wnt,0.11542110660342572
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin in cancer,0.11542110660342572
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,and oxidative stress,0.11542110660342572
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,inflammation and oxidative,0.11542110660342572
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,chronic inflammation and,0.11542110660342572
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ability of oleacein,0.11572898935864771
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,the ability of,0.10594394651307042
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,based lsdxxx inhibitors,0.06835140541082474
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,secoiridoid based lsdxxx,0.06835140541082474
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,new secoiridoid based,0.06835140541082474
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,design new secoiridoid,0.06835140541082474
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,to design new,0.06835140541082474
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,template to design,0.06835140541082474
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,as template to,0.06835140541082474
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein as template,0.06835140541082474
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,the paraquat induced,0.13457380920064088
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sh syxxxy cells,0.13457380920064088
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,in sh syxxxy,0.13457380920064088
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,related neurodegenerative disorders,0.0794814595835287
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,stress related neurodegenerative,0.0794814595835287
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxidative stress related,0.0794814595835287
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,other oxidative stress,0.0794814595835287
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,possibly other oxidative,0.0794814595835287
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,and possibly other,0.0794814595835287
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,disease and possibly,0.0794814595835287
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipid lowering therapy,0.12101797594980179
Practical guide for the use of PCSK9 inhibitors in Portugal.,in clinical practice,0.12101797594980179
Practical guide for the use of PCSK9 inhibitors in Portugal.,españa all rights,0.0780766528753188
Practical guide for the use of PCSK9 inhibitors in Portugal.,elsevier españa all,0.0780766528753188
Practical guide for the use of PCSK9 inhibitors in Portugal.,por elsevier españa,0.0780766528753188
Practical guide for the use of PCSK9 inhibitors in Portugal.,publicado por elsevier,0.0780766528753188
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiologia publicado por,0.0780766528753188
Practical guide for the use of PCSK9 inhibitors in Portugal.,de cardiologia publicado,0.0780766528753188
Practical guide for the use of PCSK9 inhibitors in Portugal.,portuguesa de cardiologia,0.0780766528753188
Practical guide for the use of PCSK9 inhibitors in Portugal.,sociedade portuguesa de,0.0780766528753188
